Contraception - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Contraception. Contraception - Pipeline Review, Half Year is built using data and information sourced from publisher proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Contraception.
- A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Contraception pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Contraception.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Spanning over 100 pages, 33 tables and 14 figures, “ Contraception - Pipeline Review, H2 2013 ” report provides information on the therapeutic development for Contraception, complete with latest updates, and special features on late-stage and discontinued projects.
In addition to covering the An Overview of Pipeline Products for Contraception, Contraception Therapeutics under Development by Companies, Contraception Therapeutics under Investigation by Universities/Institutes, Comparative Analysis, Contraception Therapeutics - Drug Profile Updates, Contraception Therapeutics - Discontinued Products, Contraception Therapeutics - Dormant Products and Contraception - Product Development Milestones. The report covers 17 companies Antares Pharma, Inc., Watson Pharmaceuticals, Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Limited, Bayer AG, TheraKine Inc., Ligand Pharmaceuticals Incorporated, Intas Pharmaceuticals Ltd., ANI Pharmaceuticals, Inc., HRA Pharma, SA, Pantarhei Bioscience BV, Hydra Biosciences, Inc., Agile Therapeutics, Inc., CG Therapeutics, Inc., Adamis Pharmaceuticals Corporation and CONRAD.
Find all healthcare market research reports under a single page at: Healthcare Market Research Reports
No comments:
Post a Comment
Note: only a member of this blog may post a comment.